---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-130763"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2024-11-26T23:59:59+00:00"
generated_at: "2026-05-29T17:54:52.173389+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Aptevo's Peter Pavlik to present ADAPTIR platform at Pep Talk; new molecule expected in early 2025

## Summary
- Peter Pavlik, PhD, will chair a 'Bi and Multispecific Biologics' session at Pep Talk conference in January 2025.
- Presentation will highlight ADAPTIR platform using clinical candidates Mipletamig and ALG.APV-527 as proof of concept.
- Aptevo has five compounds in clinical/preclinical development and plans a new molecule in early 2025.

## SEC filing metadata
- accession: 0000950170-24-130763
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2024-11-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000095017024130763/0000950170-24-130763-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000095017024130763/apvo-20241126.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-130763
- JSON: https://secwatch.observer/filing/0000950170-24-130763.json
- Plain text: https://secwatch.observer/filing/0000950170-24-130763.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.